Masimo MASI recently reported findings from the NeoPODS study, a large prospective real-world evaluation of its SET pulse oximetry technology in critically ill newborns. The study demonstrated less ...

These promising results—from an NIH-funded study that exclusively evaluated Masimo SET ® in a vulnerable, clinically fragile ...

Masimo’s NeoPODS study in critically ill newborns found its SET pulse oximetry technology delivered consistent accuracy across all skin tones, with less than 1% bias. The findings address longstanding ...

IRVINE, Calif.-- (BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced today that RD SET™ sensors with Masimo Measure-through Motion and Low Perfusion™ SET ® pulse oximetry have received FDA clearance ...

Masimo Corp.’s pulse oximetry technology avoids the dangerous under-recognition of low oxygen levels in people of color that plagues many pulse oximeters on the market, a peer-reviewed study in the ...

Masimo Corporation ( MASI) recently announced that U.S.-based Yale-New Haven Hospital has upgraded its system to Masimo SET pulse oximetry, joining a growing global roster of health organizations ...

About a week after the FDA convened its latest meeting to discuss strategies for reducing racial biases in widely available pulse oximetry technology, Masimo has released new study data suggesting ...

NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today the CE marking of Eve™, a critical congenital heart disease (CCHD) newborn screening application, for the Rad-97™ Pulse ...

IRVINE, Calif., Oct. 2, 2012 /PRNewswire/ -- Masimo (NASDAQ: MASI) today announced the conversion of Albany Medical Center (AMC), one of the biggest hospitals in the Capital (N.Y.) Region, to Masimo ...

IRVINE, Calif., Aug. 7, 2012 /PRNewswire/ -- Masimo (NASDAQ: MASI) announced today a new study in the Journal of Anesthesia demonstrates that for fluid responsiveness assessment, Masimo's noninvasive ...